The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...
We recently compiled a list of the 10 Best Metaverse Stocks To Buy According to Hedge Funds. In this article, we are going to ...
Omni mini-LED sets feature a 4K QLED mini-LED display capable of delivering up to 1,400 nits of peak brightness, and support ...
The Company also notes that Megan Baldwin, PhD, MAICD, retired from the Board as Executive Director, in accordance with ASX Listing Rules. Dr. Baldwin will continue to advance Opthea’s innovation ...
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...
Despite the introduction of therapies targeting VEGF, less than half of all treated patients with wet AMD, the most common ...
I am thrilled to further strengthen and enrich Ocular’s senior leadership team with the appointment of Namrata as Chief Business Officer. She brings a unique perspective to the role of CBO based on ...
Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024Ophthalmology Innovation Summit XIV, November 23, 2024MELBOURNE, ...
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.
Medpage Today on MSN10d
FDA Grants Market Authorization to Light-Therapy System for Dry AMDThe FDA announced marketing authorization of a form of light therapy as the first-ever treatment for dry age-related macular ...
A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback